The Effects of Oxidized Low Density Lipoprotein on Psoriasis and the Feasibility of Statin Topical Therapy in Psoriasis

Project: A - Government Institutionb - Ministry of Science and Technology

Project Details

Description

Social and economic impacts: Psoriasis affects at least 125 million people across the world. Clinical use of anti-TNF therapy which increased risk of deadly infections. Course of treatment about US $ 20,000 per person per year. Academic impacts: Chronic psoriasis with dyslipidemia is common clinical phenomena. Increased prevalence of significant coronary artery calcification in patients with psoriasis. The purpose of the project is developing the treatment of psoriasis medicine. The plan is expected to complete the objectives: The first year:To study the correlation mechanism of psoriasis and dyslipidemia. Aim (I):To investigation the relationship between dyslipidemia and psoriasis in animal model. 1. To creat dyslipidemia and Imiquimod-induced psoriasis-like animal model, which observe and confirm the disease by morphology. 2. To investigate the specific antibody expression in dyslipidemia and Imiquimod-induced psoriasis-like animal model, which observe and confirm the disease by immunohistochemistry. Aim (II):To investigate the signal pathways between dyslipidemia and psoriasis in vitro. 1. Preparation of oxidized low-density lipoprotein. 2. Determine the time and concentration of oxidized low-density lipoprotein treat with cell. 3. To prove ox-LDL indeed increased LOX-1 protein expression in Hacat cell line. 4. Make sure Hacat cell line uptake oxidized low-density lipoprotein through LOX-1 receptor. 5. To explore the mechanism which uptake oxidized low-density lipoprotein by Hacat cell line that LOX-1 silenced. The second year:To study the mechanism of Statin topical therapy used to treat psoriasis. Aim (I):To investigate the effect of statin topical therapy used to treat psoriasis in vivo. 1. Produce statin ointment. 2. To assess the effect of statin topical therapy by morphology which used to treat psoriasis in vivo.3. To assess the specific antibody expression of statin topical therapy by immunohistochemistry which used to treat psoriasis in vivo. Aim (II):To investigate the mechanisms of statin treat psoriasis in vivo. 1. Determine the time and concentration of simvastatin treat with cell. 2. To prove the TNF-α released via psoriatic keratinocytes that facilitate the expression of adhesion molecules by statin inhibition.3.To prove the TNF-α released via psoriatic keratinocytes that facilitate the expression of LOX-1 by statin inhibition. 4. To explore the mechanism of simvastatin inhibits the cytokines. The third year:To study the correlation of LOX-1 protein expression in psoriasis tissue and dyslipidemia in this country. Aim (I):Compare the accumulation of ox-LDL in psoriatic and normal skin specimens. 1.Collection of specimens: To confirm the accumulation of ox-LDL in specimens. 2. Collected specimens coordinate with retrospective study. Aim (II):To study the LOX-1 protein expression in psoriatic and normal skin specimens. 1.Collection of specimens: To confirm the LOX-1 protein expression in specimens. 2. Collected specimens coordinate with retrospective study.
StatusFinished
Effective start/end date8/1/177/31/18